Steven Cohen Fibrogen Inc Call Options Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $395,000 - $1.42 Million	-500,000 Reduced 23.81%	1,600,000 $1.38 Million
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $1.25 Million - $10.3 Million	500,000 Added 31.25%	2,100,000 $5.67 Million
Q1 2023 May 15, 2023	BUY	$15.95 - $25.18 $1.6 Million - $2.52 Million	100,000 Added 6.67%	1,600,000 $29.9 Million
Q2 2022 Aug 15, 2022	BUY	$7.94 - $12.96 $11.9 Million - $19.4 Million	1,500,000 New	1,500,000 $15.8 Million

120

62.2M

1.54M

221K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $78.7M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.